Medical/Pharmaceuticals
Dr Neal Shore joins Clarity's Clinical Advisory Board
SYDNEY, May 26, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that DrNeal Shore has joined Clarity's Clinical Advisory Board (C...
2022-05-26 21:08
2218
Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer
SHANGHAI and WARREN, N.J., May 26, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage biotechnology company developing innovative medicines to treat cancer and liver diseases, today announced that two first patients have been dosed in the U.S. andChina, respectively, in a Phase Ib/III cli...
2022-05-26 20:27
1657
111 to Announce First Quarter 2022 Unaudited Financial Results on June 16, 2022 - Conference Call to Follow
SHANGHAI, May 26, 2022 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results ...
2022-05-26 16:59
3275
Full-Life Technologies Completes $37 Million (USD) Series A Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Radiotechnology Production Platform
SHANGHAI and BRUSSELS, May 26, 2022 /PRNewswire/ -- Full-Life Technologies ("Full-Life") today announced it completed a$37 million (USD) Series A financing round to advance the development of its radiopharmaceutical oncology product pipeline and its radiotechnology production platform. The financ...
2022-05-26 12:00
1733
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based on data from the global, Phase 3 AGILE trial that demonstrated a statistically significant improvement in eve...
2022-05-26 04:45
2020
SeekIn Receives CE Mark Approval for SeekInClarity™ Cancer Treatment Response Monitoring Kit
First-of-its-Kind blood-based pan-cancer treatment response monitoring test SHENZHEN, China, May 25, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (ConformitéEuropéenne) Mark approval for SeekInClarityTM Cancer Treatm...
2022-05-25 20:30
1939
Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 25, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announcedthat it has successfully completed the dosing of first patient in phase I trial of B7H4x4-1BB bispecific antibody HBM7008 inAustralia. This study will evaluate ...
2022-05-25 17:42
2273
CONCEPT DESIGN MILESTONE FOR DHS SELF-SCREEN CHECKPOINT STATION ACHIEVED
Successful first stage design milestone for Micro-X Passenger Self screening station - Unlocks$0.7m second phase of work ADELAIDE, Australia and SEATTLE, May 24, 2022 /PRNewswire/ -- Australian hi-tech company Micro-X Ltd (ASX:MX1) (Micro-X or the Company), a leader in cold cathode x-ray technol...
2022-05-24 19:00
1754
Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis
SHANGHAI, May 24, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) presented at Digestive Disease Week (DDW) 2022 detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluatin...
2022-05-24 19:00
1650
RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting
YANTAI, China, May 23, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK, SHA: 688331), a commercial-stage biotechnology company, today announced that three abstracts for disitamab vedotin (RC48) have been selected for poster discussions by the 2022 American Society of Clinical Oncology (ASCO) Ann...
2022-05-24 10:27
1974
KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO
SYDNEY, May 23, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be presenting at two upcoming investor conferences. Dr Garner will present on behalf of Kazia at the HC ...
2022-05-23 20:30
3032
VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to Daily Growth Hormone
SHANGHAI, May 23, 2022 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, today announced positive top-line results from its pivotal phase 3 trial, a randomized, open-label, active-controlled trial that compared lonapegsomatropin (TransCo...
2022-05-23 15:57
1379
Hanmi Fine Chemical Launches 'high-tech CDMO' Business
CDMO business initiated such as mRNA vaccine raw materials·peptides 10 billion KRW invested in Hanmi Fine Chemical facility expansion SEOUL, South Korea, May 22, 2022 /PRNewswire/ -- Hanmi Fine Chemical (hereinafter Hanmi FC) a subsidiary of Hanmi Pharmaceutical Group specializing in APIs(Active...
2022-05-23 08:32
2227
WHO Goodwill Ambassador for Leprosy Elimination Recognized with WHO Director-General's Award for Global Health at 75th World Health Assembly
Ambassador will call on countries to strengthen efforts against leprosy in meetings with delegations attending WHA TOKYO, May 22, 2022 /PRNewswire/ -- WHO Goodwill Ambassador for Leprosy Elimination Yohei Sasakawa arrives inGeneva, Switzerland on May 23 for the 75th World Health Assembly, where ...
2022-05-23 00:00
2300
Meihua International Medical Technologies Co., Ltd. Receives Notification of Deficiency from Nasdaq Related to Delayed Annual Report on Form 20-F
YANGZHOU, China, May 20, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today announced that on May 18,...
2022-05-20 22:57
7265
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, May 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of can...
2022-05-19 22:39
2511
I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
SHANGHAI and GAITHERSBURG, MD., May 19 , 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors at 8 a.m. EST on...
2022-05-19 20:00
1830
Ascentage Pharma Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in EMBO Molecular Medicine
SUZHOU, China and ROCKVILLE, Md., May 18, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a new preclinical study, conducted by the rese...
2022-05-18 22:06
2330
OriCiro Genomics expand into Boston, Open new office in North America
TOKYO, May 18, 2022 /PRNewswire/ -- OriCiro Genomics K.K. a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapeutics and synthetic biology, today announced the open US office in North America. In the midst of the genomic revolution, OriCiro is on a mi...
2022-05-18 22:00
2012
Vela Diagnostics Launches Multiplex PCR-Based Test for Detecting UTI Pathogens and Antimicrobial Resistance Genes
FAIRFIELD, N.J., 17 May, 2022 /PRNewswire/ -- Vela Diagnostics announced today the launch of its new PathoKey® MP UTI ID and AMR PCR Test for research use only (RUO*). This multiplex PCR-based test allows for the in vitro detection and differentiation of 14 pathogens that cause urinary tract in...
2022-05-17 22:00
2313
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9278
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7753